Indonesia

Reimbursed Care Access

Indonesia permits licensed medical use of ketamine (as an approved anesthetic) and has a registered esketamine product (Spravato) with BPOM marketing authorization; both are available only through regulated medical channels and are not routinely reimbursed by public insurance for psychiatric indications. All classical psychedelic compounds requested (psilocybin, MDMA, DMT, 5-MeO-DMT, ayahuasca, mescaline, 2C‑X) are controlled or treated as illegal under Indonesian narcotics/psikotropika regulation and enforcement, with no routine medical reimbursement pathways except within approved clinical research or where a narrowly applicable regulatory exception exists. Ibogaine/iboga occupy a more ambiguous/legal‑gray status in many jurisdictions globally and in Indonesia there is limited public evidence of an authorized medical pathway; therefore access is effectively nonexistent outside informal/underground settings or research contexts.